The Utility of ODM-201 in CRPC

Video

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).

Clinical Pearls

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, on the utility of the androgen receptor inhibitor ODM-201 for the treatment of castration-resistant prostate cancer (CRPC).

  • In phase I and II multinational trials, favorable results have been observed regarding PSA kinetics modulation
  • The organic structure of ODM-201 seems to cause the agent to have a much lower penetration through the blood-brain barrier
  • The efficacy of ODM-201 is being measured in terms of its impact on radiographic disease, PSA, and the androgen receptor
  • ODM-201 has been studied in patients prior to and following chemotherapy, as well as in patients who have and have not received abiraterone
  • Additional trials are being planned to analyze safety, efficacy, and tolerability
  • ODM-201 will be studied in a large trial of non-metastatic patients
Recent Videos
Related Content
Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients

Brexu-cel Achieves Strong CNS and Systemic Responses in Adult B-ALL Patients

Jordyn Sava
November 22nd 2024
Article

Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.

Read More

Transforming Prostate Cancer Care Through Personalized Medicine

Transforming Prostate Cancer Care Through Personalized Medicine

Jordyn Sava;Adam Weiner, MD
July 1st 2024
Podcast

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

Listen

FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings

FGFR-Altered NMIBC Treatment Advances With TAR-210 Findings

Jordyn Sava
November 21st 2024
Article

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive bladder cancer.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

Jordyn Sava;Nazli Dizman, MD
April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab

Optimizing Treatment in Myeloma With Biweekly Dosing of Talquetamab

Jordyn Sava
November 20th 2024
Article

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple myeloma.

Read More

177Lu-PSMA-I&T Shows PFS Benefit in mCRPC

177Lu-PSMA-I&T Shows PFS Benefit in mCRPC

Jordyn Sava
November 18th 2024
Article

The ECLIPSE trial, a pivotal, phase 3, multi-center, open-label, randomized clinical study, has met its primary end point in metastatic castration-resistant prostate cancer.

Read More